Global Shifts & Investment Strategies: Embracing Uncertain Times for Health Ventures

Evelyn Pau joined Amplitude as a Principal in August 2024. She works directly with Amplitude’s portfolio companies while supporting the deal team on active diligence and nomination. 

Prior to joining Amplitude, Evelyn was the Vice President, Investment Banking at Bloom Burton & Co., a healthcare-focused investment banking firm. At Bloom Burton, her responsibilities included deal origination, strategic advisory, and venture creation for pharmaceutical, biotechnology, and healthcare companies. Previous to that, Evelyn was a Business Development Analyst at Tornado Medical Systems (acquired by Bruker) and a Research Fellow at SECOR Consulting (acquired by KPMG). She completed her PhD in immunology at the University of Toronto, specializing in the genetics of lupus, and her BMSc (Hons) in microbiology and immunology at Western University.

Cheryl leads the country’s premier life sciences practice, providing both U.S and Canadian legal advice. She advises the industry’s largest investors and most innovative startups on highly complex transactions worldwide. With an international reputation for quality and helping clients advance their strategies, Cheryl combines a deep knowledge of the market with a business-minded practical approach.   

 
 Cheryl is the International Chair, Life Sciences at Mintz, a leading AmLaw 100 firm of 700 lawyers, of whom 250 are dedicated to Health / Life Sciences. She represents the entire spectrum of biotech, medical device and health technology companies, from start-ups to large public companies, as well as venture capitalists, investment banks and academic medical centers.   

Cheryl is widely recognized for her long track record of helping life sciences companies at all stages formulate and evolve their domestic and international growth strategies, source capital, and develop and optimize their corporate and tax structures. She has extensive experience advising on venture and later-stage financings, IPOs, mergers and acquisitions, licensing transactions and joint ventures or alliances with strategic partners.  
   
Cheryl has also been recognized as one of WXN’s Top 100 of Canada’s Most Powerful Women 4 times and was inducted into the WXN Most Powerful Women Hall of Fame, as well as Canada’s Top 25 Women of Influence (No. 1 in Professional Services category). Cheryl has been  repeatedly recognized by LMG Life Sciences as Canadian Finance & Transactional Lawyer of the Year, and for leading the Impact Deal of the Year, and is rated Band 1 in Chambers for Life Sciences: Corporate/Commercial. She was also 1 of 5 attorneys shortlisted for the LMG Life Sciences Awards for U.S. Venture Capital Attorney of the Year.   
   
Cheryl is involved in numerous charitable endeavors, including, among others, having served as a trustee for The Hospital for Sick Children and as founder of Canadian Women in Life Sciences and UJA: Genesis. Cheryl is a graduate of Harvard Law School.  

Dr. Dante Morra is a visionary leader in Canadian healthcare, recognized for transforming systems and driving impactful change. As the Founder and Chair of the CAN Health Network, he has revolutionized how Canadian medtech companies succeed in the healthcare sector, fostering innovation and economic growth.

Previously, he served as Chief Clinical Innovation Officer and President of THP Solutions, advancing technological solutions and operational efficiencies. He also founded Insight Health Solutions, a $45 million annual initiative that supports hospital operations. As the inaugural Chief of Staff at Trillium Health Partners, he oversaw 1,400 physicians and led Canada’s largest hospital merger, unifying Mississauga’s hospitals to redefine care delivery and system integration. 

Philip serves as the Life Sciences Trade Commissioner at the Consulate General of Canada in Boston. In this role, he actively works with and supports Canadian Life Sciences companies that are seeking to grow their business through partnering, capital raising, sales and technology commercialization in New England and the USA.

Philip uses his relationships with New England based companies, investors, customers, and research institutions to support innovative Canadian companies and promotes the advantages Canada offers to the New England Life Sciences community.

As an international and business development executive with over 30 years of global experience in the medical device and pharmaceutical industries, Philip has enabled businesses to grow, expand internationally, and develop and launch new products and technologies. A passion is diabetes technologies that help enable patients better manage their disease in a cost effective manner.